In the rapidly advancing field of biotechnology, consistent technological innovations, escalating merger and acquisition activities, and advancing product pipelines are fueling significant growth. This sector's robust prospects are further strengthened by unwavering demand, assuring its continuance into the future.
Against this backdrop, investors might want to add biotech stocks Acorda Therapeutics, Inc. (ACOR), Organogenesis Holdings Inc. (ORGO), and Equillium, Inc. (EQ) to the watchlist in 2024 to capitalize on the industry tailwinds.
